DE69232815T2 - Lungentransfektion durch verabreichung von transgenen im aerosol - Google Patents

Lungentransfektion durch verabreichung von transgenen im aerosol

Info

Publication number
DE69232815T2
DE69232815T2 DE69232815T DE69232815T DE69232815T2 DE 69232815 T2 DE69232815 T2 DE 69232815T2 DE 69232815 T DE69232815 T DE 69232815T DE 69232815 T DE69232815 T DE 69232815T DE 69232815 T2 DE69232815 T2 DE 69232815T2
Authority
DE
Germany
Prior art keywords
transgenes
aerosol
administration
transfection
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232815T
Other languages
English (en)
Other versions
DE69232815D1 (de
Inventor
J Debs
Ning Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE69232815D1 publication Critical patent/DE69232815D1/de
Application granted granted Critical
Publication of DE69232815T2 publication Critical patent/DE69232815T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69232815T 1991-12-17 1992-12-17 Lungentransfektion durch verabreichung von transgenen im aerosol Expired - Fee Related DE69232815T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80929191A 1991-12-17 1991-12-17
US07/972,135 US5858784A (en) 1991-12-17 1992-11-05 Expression of cloned genes in the lung by aerosol- and liposome-based delivery
PCT/US1992/011008 WO1993012756A2 (en) 1991-12-17 1992-12-17 Transfection of lung via aerosolized transgene delivery

Publications (2)

Publication Number Publication Date
DE69232815D1 DE69232815D1 (de) 2002-11-21
DE69232815T2 true DE69232815T2 (de) 2003-09-18

Family

ID=27123206

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232815T Expired - Fee Related DE69232815T2 (de) 1991-12-17 1992-12-17 Lungentransfektion durch verabreichung von transgenen im aerosol

Country Status (8)

Country Link
US (3) US5858784A (de)
EP (1) EP0619742B1 (de)
JP (2) JPH07505134A (de)
AU (1) AU679170B2 (de)
CA (1) CA2126103C (de)
DE (1) DE69232815T2 (de)
ES (1) ES2185624T3 (de)
WO (1) WO1993012756A2 (de)

Families Citing this family (365)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
US8153602B1 (en) * 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
CA2126101A1 (en) * 1991-12-17 1993-06-24 Robert J. Debs Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1994005782A1 (en) * 1992-09-10 1994-03-17 Trustees Of Tufts College In vivo production of transgenic organ by introducing the transgene via lumen
WO1994027435A1 (en) 1993-06-01 1994-12-08 Life Technologies, Inc. Genetic immunization with cationic lipids
US5688677A (en) * 1993-10-13 1997-11-18 Genzyme Corporation Deoxyribonucleic acids containing inactivated hormone responsive elements
US6887856B1 (en) 1993-10-15 2005-05-03 University Of Pittsburgh Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
WO1995010538A1 (en) * 1993-10-15 1995-04-20 The University Of North Carolina At Chapel Hill Dna encoding the human p2u receptor and null cells expressing p2u receptors
FR2711523B1 (fr) * 1993-10-26 1996-02-16 Transgene Sa Procédé de préparation d'un aérosol viral.
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
AUPM747694A0 (en) * 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
FR2727679B1 (fr) * 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US6383814B1 (en) * 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
WO1996020013A1 (en) * 1994-12-24 1996-07-04 Cambridge University Technical Services Limited Improvements in or relating to endometrial function
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
JP4335310B2 (ja) * 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
AU771241B2 (en) * 1995-06-07 2004-03-18 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7034007B1 (en) 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
AU7078396A (en) * 1995-09-27 1997-04-30 Regents Of The University Of California, The Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes
US5869715A (en) * 1995-09-27 1999-02-09 The Reagents Of The University Of California Polyfunctional cationic cytofectins
US6121247A (en) * 1996-03-29 2000-09-19 The Johns Hopkins University Therapy for allergic diseases
US6156567A (en) * 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
AU738838B2 (en) * 1996-09-12 2001-09-27 Valentis, Inc. Compositions and methods for pulmonary gene delivery
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
WO1998017321A1 (en) 1996-10-24 1998-04-30 Vanderbilt University Gene delivery and expression in areas inaccessible to direct protein delivery
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US6034072A (en) * 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5965542A (en) * 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
US20030229040A1 (en) * 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6559129B1 (en) * 1997-03-21 2003-05-06 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
US5958894A (en) * 1997-04-04 1999-09-28 Megabios Corporation Amphiphilic biguanide derivatives
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
CA2205076A1 (en) 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
EP1007673B1 (de) 1997-07-30 2008-12-17 Emory University Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US20050142126A1 (en) * 1997-08-20 2005-06-30 Bernard Knoops Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders
ES2245042T3 (es) 1997-09-24 2005-12-16 The Regents Of The University Of California Vectores de lentivirus de no primates y sistemas de empaquetamiento.
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) * 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US7157098B1 (en) * 1998-01-06 2007-01-02 Roman Perez-Soler Gene therapy of tumors using non-viral delivery system
TW520294B (en) * 1998-01-08 2003-02-11 Res Dev Foundation Stabilization of lipid: DNA formulations during nebulization
US6375980B1 (en) * 1998-01-08 2002-04-23 Research Development Foundation Stabilization of lipid:DNA formulations during nebulization
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
WO1999039741A2 (en) 1998-02-03 1999-08-12 Inex Pharmaceuticals Corporation Systemic delivery of serum stable plasmid lipid particles for cancer therapy
US6158431A (en) * 1998-02-13 2000-12-12 Tsi Incorporated Portable systems and methods for delivery of therapeutic material to the pulmonary system
US6221848B1 (en) 1998-05-11 2001-04-24 University Of Pittsburgh Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
JP2002515513A (ja) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド 核酸の肺送達のための組成物および方法
AU4007899A (en) * 1998-05-21 1999-12-06 Isis Pharmaceuticals, Inc. Compositions and methods for the pulmonary delivery of nucleic acids
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
CA2333901A1 (en) * 1998-08-03 2000-02-24 East Carolina University Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
EP1839648A3 (de) * 1998-11-12 2007-11-21 Transave, Inc. Inhalationssystem
AU766703B2 (en) * 1998-11-12 2003-10-23 Frank G Pilkiewicz An inhalation system
JP4854853B2 (ja) 1998-11-12 2012-01-18 ライフ テクノロジーズ コーポレーション トランスフェクション薬剤
US6855549B1 (en) 1998-11-23 2005-02-15 The University Of Iowa Research Foundation Methods and compositions for increasing the infectivity of gene transfer vectors
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) * 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
ATE279206T1 (de) * 1999-02-24 2004-10-15 Univ North Carolina State Zusammensetzungen zur modulierung der schleimsekretion
AU4031700A (en) * 1999-04-06 2000-11-02 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation,allergy(ies) and surfactant depletion
JP4932086B2 (ja) * 1999-04-08 2012-05-16 インターセル ユーエスエイ、インコーポレイテッド 経皮的免疫のための乾燥製剤
AU7595000A (en) * 1999-09-23 2001-04-24 General Hospital Corporation, The Methods for potentiating antisense rna techniques
AU784123B2 (en) 1999-10-13 2006-02-09 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU6124601A (en) * 2000-05-10 2001-11-20 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US20020106368A1 (en) * 2000-07-28 2002-08-08 Adrian Bot Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
WO2002064162A2 (en) * 2001-02-13 2002-08-22 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
US20030203865A1 (en) * 2001-04-30 2003-10-30 Pierrot Harvie Lipid-comprising drug delivery complexes and methods for their production
US20030077829A1 (en) * 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
WO2002097116A2 (en) * 2001-05-30 2002-12-05 The Scripps Research Institute Delivery system for nucleic acids
EP1424898A4 (de) * 2001-08-20 2008-04-02 Transave Inc Behandlung von karzinomen durch inhalation von stabilen platinhaltigen formulierungen
JP2005502653A (ja) * 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド 肺ガンの治療方法
WO2003037302A1 (en) * 2001-10-30 2003-05-08 Windsor J Brian Method and system for the co-isolation of cognate dna, rna and protein sequences and method for screening co-isolates for defined activities
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
IL161733A0 (en) * 2001-11-02 2005-11-20 Insert Therapeutics Inc Methods and compositions for therapeutic use of rna interference
CN100384865C (zh) * 2001-11-02 2008-04-30 嵌入治疗公司 用于rna干扰的治疗用途的方法及组合物
AUPR894201A0 (en) * 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
JP2005514393A (ja) * 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
JP2005530704A (ja) * 2002-03-05 2005-10-13 トランセイブ， インク． 細胞内感染を予防及び治療するための吸入システム
WO2004007664A2 (en) * 2002-05-28 2004-01-22 Maxygen, Inc. Nucleic acid vectors
WO2004002453A1 (en) 2002-06-28 2004-01-08 Protiva Biotherapeutics Ltd. Method and apparatus for producing liposomes
KR20050038011A (ko) * 2002-08-02 2005-04-25 트랜세이브, 인코포레이티드 백금 응집체 및 이의 제조 방법
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
ES2686361T3 (es) * 2002-10-29 2018-10-17 Insmed Incorporated Liposomas que comprenden un aminoglucósido para el tratamiento de infecciones pulmonares
TW200428067A (en) * 2002-11-01 2004-12-16 Kopin Corp Multi-domain vertical alignment liquid crystal display
EP2491943B1 (de) 2003-02-04 2018-10-10 Cornell Research Foundation, Inc. Verfahren zum Verhindern des Übergangs der Mitochondrienpermeabilität
CA2524258C (en) 2003-05-01 2012-08-07 Cornell Research Foundation, Inc. Carrier complexes comprising cationic peptides for delivering molecules to cells
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2005004913A1 (ja) * 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
AU2004257373B2 (en) * 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
WO2005023292A1 (en) 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
NZ592917A (en) 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
EP1687066B1 (de) 2003-11-14 2012-08-29 Brigham and Women's Hospital, Inc. Verfahren zur modulation der immunität
EP1707629B1 (de) * 2003-12-03 2011-06-08 Chugai Seiyaku Kabushiki Kaisha Expressionssystem mit einem säuger-beta-actin-promotor
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
JP4931604B2 (ja) 2004-01-23 2012-05-16 コーネル リサーチ ファウンデイション インコーポレイテッド 酸化的損傷を低減する方法
AU2005206053A1 (en) * 2004-01-23 2005-08-04 Keio University Support accumulating in injured part in vascular channel
WO2005078848A2 (en) * 2004-02-11 2005-08-25 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
EP1729786A4 (de) * 2004-03-18 2008-03-26 Transave Inc Verabreichung von cisplatin durch inhalation
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
WO2005112957A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
ATE536418T1 (de) 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc Lipidverkapselte interferenz-rna
EP1781593B1 (de) 2004-06-07 2011-12-14 Protiva Biotherapeutics Inc. Kationische lipide und verwendungsverfahren
JP2008504827A (ja) 2004-07-02 2008-02-21 プロチバ バイオセラピューティクス インコーポレイティッド 免疫賦活性ｓｉＲＮＡ分子およびその使用方法
US20060051405A1 (en) * 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
US20060045849A1 (en) * 2004-08-24 2006-03-02 Farhan Taghizadeh Method of customizing the fragrance of nasal medications
KR20070089693A (ko) * 2004-11-08 2007-08-31 트랜세이브, 인코포레이티드 지질-기재 플래티넘 화합물 제형을 복막내 투여하여 암을치료하는 방법
WO2006053430A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
NZ577196A (en) 2005-01-20 2011-06-30 Biomarck Pharmaceuticals Ltd Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
ES2381201T3 (es) 2005-03-31 2012-05-24 Calando Pharmaceuticals, Inc. Inhibidores de la subunidad 2 de la ribonucleótido-reductasa y utilizaciones de los mismos
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
US20110178092A1 (en) * 2005-06-22 2011-07-21 Akbar Ali HIV-1 Protease Inhibitors
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
CA2947335A1 (en) 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
EP1951737A4 (de) * 2005-11-01 2009-07-01 Alnylam Pharmaceuticals Inc Rnai-hemmung von influenza-virus-neubildungen
EP1948674A4 (de) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc Modifizierte sirna-moleküle und anwendungen davon
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
PL1962805T3 (pl) 2005-12-08 2017-01-31 Insmed Incorporated Kompozycje środków przeciwzapalnych oparte na lipidach do leczenia infekcji płucnych
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
EP1994043A4 (de) 2006-02-10 2009-05-20 Univ Cincinnati Phosphatasehemmer-protein 1 als regulator der herzfunktion
KR100745833B1 (ko) 2006-03-06 2007-08-02 고려대학교 산학협력단 양이온성 골드 나노입자와 유전자의 복합체 조성물
WO2007109097A2 (en) * 2006-03-16 2007-09-27 Alnylam Pharmaceuticals, Inc. RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
US8968702B2 (en) * 2006-03-30 2015-03-03 Duke University Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
US20090317335A1 (en) * 2006-04-20 2009-12-24 Wenbin Lin Hybrid Nanomaterials as Multimodal Imaging Contrast Agents
CA2652770A1 (en) 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
CN103990111B (zh) * 2006-07-26 2016-08-31 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽
KR100825519B1 (ko) * 2007-01-05 2008-04-25 주식회사 바이오폴리메드 키토산 기재 고분자 접합체 및 그 제조방법
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
CN101754682B (zh) 2007-05-16 2014-11-12 布里格姆妇女医院 突触核蛋白病的治疗
CA2713150C (en) 2008-02-07 2016-01-05 Cornell University Methods for preventing or treating insulin resistance
WO2009139939A2 (en) * 2008-02-22 2009-11-19 The University Of North Carolina At Chapel Hill Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
CN106975070A (zh) 2008-02-26 2017-07-25 康奈尔大学 用于防止和治疗急性肾损伤的方法
US8114983B2 (en) 2008-04-04 2012-02-14 Calando Pharmaceuticals, Inc. Compositions and use of EPAS1 inhibitors
EP2265630B1 (de) 2008-04-14 2014-10-29 The General Hospital Corporation Auf plectin-1 gerichtete wirkstoffe für den nachweis und die behandlung von duktalem adenokarzinom des pankreas
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
SG10201510586PA (en) 2008-06-30 2016-01-28 Mesoblast Inc Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
EP2361098B1 (de) 2008-10-31 2019-08-28 The General Hospital Corporation Zusammensetzungen und verfahren zur abgabe einer substanz an ein biologisches target
EP2344519B1 (de) 2008-11-07 2016-09-28 The General Hospital Corporation C-terminale fragmente von glucagon-ähnlichem peptid-1 (glp-1)
TW201031436A (en) * 2009-02-16 2010-09-01 Univ Nat Taiwan Pharmaceutical composition for inhalation delivery and fabrication method thereof
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
CN103933542A (zh) 2009-03-20 2014-07-23 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
JP2010251707A (ja) * 2009-03-27 2010-11-04 Fujitsu Ltd 配線基板及び半導体装置
EP2756845B1 (de) 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Verfahren und Zusammensetzungen für spezifische KRAS-Hemmung mit asymmetrischer Doppelstrang-RNA
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
JP5909182B2 (ja) 2009-08-12 2016-04-26 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
EP3318264A1 (de) 2009-08-24 2018-05-09 Stealth Peptides International, Inc. Verfahren und zusammensetzungen zur prävention oder behandlung ophthalmischer leiden
US20120208750A1 (en) 2009-09-29 2012-08-16 Joslin Diabetes Center, Inc. Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis
EP2944317A1 (de) * 2009-10-05 2015-11-18 Cornell University Verfahren zur Prävention und Behandlung von Herzinsuffizienz
PL3338765T3 (pl) 2009-12-01 2019-06-28 Translate Bio, Inc. Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
EP3090754A1 (de) 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Verfahren zur vorbeugung oder behandlung einer gefässverschlussverletzung
US20130190244A1 (en) 2009-12-31 2013-07-25 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CA2787331A1 (en) 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
WO2011106525A2 (en) 2010-02-26 2011-09-01 The Brigham And Women's Hospital, Inc. Methods of treating cerebral amyloid angiopathy
EP3560508A1 (de) 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Kombinationstherapien mit verwendung von cyclosporin und aromatischen kationischen peptiden
AU2011246893A1 (en) 2010-04-29 2012-11-08 Hadasit Medical Research Service And Development Co. Ltd. Methods and compositions for treating hepatitis with anti-CD3 immune molecule therapy
EP3450447A1 (de) 2010-05-03 2019-03-06 Stealth Peptides International, Inc. Aromatisch-kationische peptide und verwendungen davon
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
CA2804404C (en) 2010-07-09 2020-10-20 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
US9447027B2 (en) 2010-10-22 2016-09-20 The General Hospital Corporation Treating long QT syndrome
US10016414B2 (en) 2010-11-12 2018-07-10 University Of Massachusetts Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
EP3488941A1 (de) 2011-03-24 2019-05-29 Cornell University Aromatisch-kationische peptide und verwendungen davon
EP2691515A2 (de) 2011-03-31 2014-02-05 President and Fellows of Harvard College Einmalige population aus regulatorischen t-zellen zur regulierung von geweberegeneration und wundheilung
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
JP6049712B2 (ja) 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子
JP6157481B2 (ja) 2011-09-29 2017-07-05 メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ 芳香族陽イオン性ペプチドおよびその使用方法
GB201118704D0 (en) * 2011-10-28 2011-12-14 Univ Oxford Cystic fibrosis treatment
JP2014533953A (ja) 2011-11-17 2014-12-18 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 治療用ｒｎａスイッチ組成物及び使用方法
EP2788013A4 (de) 2011-12-09 2015-08-19 Stealth Peptides Int Inc Aromatisch-kationische peptide und verwendungen davon
EP3078384A1 (de) 2012-02-22 2016-10-12 Stealth Peptides International, Inc. Verfahren und zusammensetzungen zur prävention oder behandlung von augenleiden
EP2817021B1 (de) 2012-02-23 2019-01-02 Cornell University Aromatisch-kationische peptide und verwendungen davon
US9603897B2 (en) 2012-03-12 2017-03-28 Massachusetts Institute Of Technology Methods for treating tissue damage associated with ischemia with apolipoprotein D
WO2013155447A1 (en) 2012-04-13 2013-10-17 Children's Medical Center Corporation Tiki inhibitors
JP6402097B2 (ja) 2012-05-21 2018-10-10 インスメッド インコーポレイテッド 肺感染症を処置するためのシステム
EP3884949A1 (de) 2012-06-08 2021-09-29 Translate Bio, Inc. Pulmonale verabreichung von mrns an nicht pulmonale zielzellen
CA2880648A1 (en) 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
WO2014025808A1 (en) 2012-08-06 2014-02-13 The General Hospital Corporation Curcumin analogs
JP2015530387A (ja) 2012-09-04 2015-10-15 エライゾン ファーマシューティカルズ， エルエルシー 脂質複合体化シスプラチンによる肺癌の再発防止
EP3586862B1 (de) 2012-10-22 2021-12-08 Stealth Peptides International, Inc. Verfahren zur verringerung der gefahren im zusammenhang mit herzinsuffizienz und damit zusammenhängenden faktoren
WO2014065860A1 (en) 2012-10-24 2014-05-01 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
ES2743039T3 (es) 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
JP2016506391A (ja) 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法
EP2938339B1 (de) 2012-12-27 2020-08-19 Massachusetts Eye & Ear Infirmary Behandlung von rhinosinusitis mit p-glycoprotein-hemmern
CA2930987A1 (en) 2013-01-11 2014-07-17 Massachusetts Eye And Ear Infirmary Cyp450 lipid metabolites reduce inflammation and angiogenesis
EP2851086A1 (de) 2013-09-20 2015-03-25 Sanofi Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
US20160002316A1 (en) 2013-02-22 2016-01-07 Joslin Diabetes Center Serpins: methods of therapeutic beta-cell regeneration and function
EP2769732A1 (de) 2013-02-22 2014-08-27 Sanofi Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
CN105517533A (zh) 2013-03-01 2016-04-20 康德生物医疗技术公司 治疗线粒体疾病的方法
HUE046924T2 (hu) 2013-03-01 2020-03-30 Stealth Biotherapeutics Corp Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra
WO2014160221A1 (en) 2013-03-13 2014-10-02 The General Hospital Corporation Photoswitchable hdac inhibitors
US9757468B2 (en) 2013-03-13 2017-09-12 The Regents Of The University Of California Intranasal administration of guanidinylated aminoglycosides
JP2016515127A (ja) 2013-03-14 2016-05-26 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ジペプチド及びトリペプチドエポキシケトンプロテアーゼ阻害剤
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
SG11201507366RA (en) 2013-03-15 2015-10-29 Gen Hospital Corp Glycine, mitochondrial one-carbon metabolism, and cancer
JP2016522196A (ja) 2013-05-14 2016-07-28 ステルス バイオセラピューティックス コープ 左室リモデリングの予防または治療のための方法
WO2014197818A2 (en) 2013-06-07 2014-12-11 The General Hospital Corporation Small molecule activators of nrf2 pathway
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2014210062A1 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
US9877997B2 (en) 2013-06-26 2018-01-30 Stealth Biotherapeutics Corp Methods and compositions for regulating SRCA2A expression levels in myocardial infarction
WO2014210056A1 (en) 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
US20160166633A1 (en) 2013-08-02 2016-06-16 Stealth Bio Therapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
WO2015034996A1 (en) 2013-09-06 2015-03-12 The General Hospital Corporation Imaging brown adipose tissue with curcumin derivatives
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
JP6590802B2 (ja) 2013-11-06 2019-10-16 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体
JP2016540762A (ja) 2013-12-02 2016-12-28 ステルス バイオセラピューティックス コープ 白斑の治療のための組成物及び方法
WO2015103643A2 (en) 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists
AU2015237200A1 (en) 2014-03-27 2016-10-06 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US10238675B2 (en) 2014-05-15 2019-03-26 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
EP3143166A4 (de) 2014-05-16 2018-04-18 University of Massachusetts Behandlung von chronischer myelogener leukämie (cml)
EP3502132A1 (de) 2014-05-28 2019-06-26 Stealth BioTherapeutics Corp Therapeutische zusammensetzungen mit kleinen therapeutischen molekülen und verwendungen davon
CA2950428C (en) 2014-05-28 2022-11-29 Stealth Biotherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EP3151827A4 (de) 2014-06-04 2018-01-24 Tersus Pharmaceuticals, LLC Verfahren zur behandlung von chronisch trockenen augen mit c16:1n7-palmitoleat und derivaten davon
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
CA2952615A1 (en) 2014-06-17 2015-12-23 Stealth Biotherapeutics Corp Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
WO2016025480A1 (en) 2014-08-11 2016-02-18 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
CA2958585C (en) 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
JP6731404B2 (ja) 2014-10-14 2020-07-29 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 光線力学療法、ｘ線誘起光線力学療法、放射線療法、化学療法、免疫療法、及びこれらの任意の組み合わせのためのナノ粒子
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
WO2016077240A2 (en) 2014-11-10 2016-05-19 Forge Life Science, Llc Anti-hcmv compositions and methods
CN107438435B (zh) 2014-11-10 2020-12-04 埃弗里斯生物有限责任公司 抗-hcmv组合物和方法
WO2016077382A2 (en) 2014-11-11 2016-05-19 Massachusetts Eye & Ear Infirmary Conjunctivitis vaccines
WO2016100401A1 (en) 2014-12-15 2016-06-23 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
JP2018501322A (ja) 2015-01-12 2018-01-18 チルドレンズ メディカル センター コーポレーション トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CA2982129A1 (en) 2015-04-08 2016-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Viral gene therapy as treatment for cholesterol storage disease or disorder
EP3292206B8 (de) 2015-05-07 2022-02-09 Takeda Pharmaceutical Company Limited Glucocerebrosidase gentherapie von morbus parkinson
EP3302525A2 (de) 2015-06-05 2018-04-11 Novartis AG Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
RU2731644C2 (ru) 2015-09-09 2020-09-07 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
WO2017059338A1 (en) 2015-10-02 2017-04-06 Cornell University Enzyme-responsive peptide nanofiber compositions and uses thereof
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
JOP20200228A1 (ar) 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
CN116196389A (zh) 2016-01-06 2023-06-02 康德生物医疗有限公司 用于预防和治疗杜氏肌肉萎缩症的方法和组合物
US11408900B2 (en) 2016-01-15 2022-08-09 Massachusetts Eye And Ear Infirmary Secreted P-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
CN117205298A (zh) 2016-05-19 2023-12-12 康德生物医疗有限公司 用于预防和治疗线粒体肌病的组合物和方法
JP7090034B2 (ja) 2016-05-20 2022-06-23 ザ ユニバーシティ オブ シカゴ 化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
WO2017218355A1 (en) 2016-06-15 2017-12-21 Counterpoint Biomedica Llc Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells
US10449230B2 (en) 2016-10-06 2019-10-22 The Regents Of The University Of California Polymyxin derived cell penetrating scaffolds
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
US20200054660A1 (en) 2016-12-09 2020-02-20 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy
EP3939605A1 (de) 2016-12-09 2022-01-19 Akston Biosciences Corporation Insulin-fc-fusionen und verfahren zur verwendung
US10913779B2 (en) 2017-01-25 2021-02-09 Counterpoint Biomedica Llc Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
EP3641814A4 (de) 2017-06-19 2021-06-23 Medicenna Therapeutics Inc. Verwendungen und verfahren für il-2-superagonisten, agonisten und fusionen davon
CA3068010A1 (en) 2017-06-20 2018-12-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions
US20200155648A1 (en) 2017-06-28 2020-05-21 Children's Medical Center Corporation Promoting lung growth
KR20200032722A (ko) 2017-07-27 2020-03-26 노파르티스 아게 부분절단효소 내성 trem2 변이체
BR102017016440A2 (pt) * 2017-07-31 2019-03-19 Universidade Federal Do Rio Grande Do Sul Composição para terapia gênica do sistema nervoso central, processo de obtenção e uso da mesma
WO2019028250A1 (en) 2017-08-02 2019-02-07 The University Of Chicago NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF
CA3072200A1 (en) 2017-08-08 2019-02-14 Memorial Sloan Kettering Cancer Center Use of braf inhibitors for treating cutaneous reactions caused by treatment with a mek inhibitor
EP3664834A1 (de) 2017-08-11 2020-06-17 Dana Farber Cancer Institute, Inc. Verwendung eines botulinumtoxinmittels zur behandlung von plasmazellstörungen
US11821003B2 (en) 2017-08-14 2023-11-21 Sanford Burnham Prebys Medical Discovery Institute Cardiogenic mesoderm formation regulators
WO2019036575A1 (en) 2017-08-18 2019-02-21 Amgen Inc. MCL-1 PROTEIN INHIBITING COMPOUNDS
EP3676270A1 (de) 2017-08-29 2020-07-08 Amgen Inc. Makrocyclische verbindungen zur hemmung des mcl-1-proteins
WO2019046668A1 (en) 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
WO2019079519A1 (en) 2017-10-18 2019-04-25 Forge Life Science, Llc BROAD SPECTRUM ANTIVIRAL COMPOSITIONS AND METHODS
AU2018388529A1 (en) 2017-12-18 2020-06-18 The General Hospital Corporation Glycoengineering
WO2019143969A1 (en) 2018-01-18 2019-07-25 Claudio Maldonado Treating microvascular dysfunction
US20210363587A1 (en) 2018-02-07 2021-11-25 St. Jude Children's Research Hospital EPIGENETIC HISTONE REGULATION MEDIATED BY CXorf67
WO2019169202A1 (en) 2018-02-28 2019-09-06 The Johns Hopkins University Bacterial biofilms and cancer
US11274105B2 (en) 2018-03-05 2022-03-15 Amgen Inc. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US20190314324A1 (en) 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
CN112424352A (zh) 2018-05-11 2021-02-26 阿尔法阿诺麦里克公司 包括7′-5′-α-异头双环糖核苷的寡核苷酸缀合物
JP2021533181A (ja) 2018-06-13 2021-12-02 アンフィスタ セラピューティクス リミテッド ＵｃｈＬ５を標的化するための二機能性分子
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
WO2019238817A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting rpn11
WO2020012331A1 (en) 2018-07-09 2020-01-16 St. Jude Children's Research Hospital Use of il-12 to alter epigenetic effector programs in cd8 t cells
WO2020023806A1 (en) 2018-07-25 2020-01-30 The Johns Hopkins University Compositions and methods for generation of heart field-specific progenitor cells
EP3843845A4 (de) 2018-08-29 2022-05-11 University Of Massachusetts Hemmung von proteinkinasen zur behandlung von friedreich-ataxie
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
AU2019359872A1 (en) 2018-10-16 2021-05-27 The Johns Hopkins University Compositions and methods for treating vascular Ehlers Danlos Syndrome and associated disorders
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
AU2019392670A1 (en) 2018-12-06 2021-07-01 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of Sengers syndrome
US20220136051A1 (en) 2019-02-22 2022-05-05 St. Jude Children's Research Hospital Methods for identifying and improving t cell multipotency
EP3930849A1 (de) 2019-02-28 2022-01-05 Kezar Life Sciences Thiazolderivate als proteinsekretionsinhibitoren
CN113905724A (zh) 2019-04-15 2022-01-07 儿童医学中心公司 包含线粒体的雾化组合物及其使用方法
EP3976646A4 (de) 2019-05-28 2023-04-19 Shanghaitech University Zusammensetzung und verfahren zur behandlung von ektodermaler dysplasie 2, clouston-typ
AU2020316449A1 (en) 2019-07-24 2022-02-10 Stealth Biotherapeutics Inc. The peptidomimetic compound (R)-2-amino-N-((S)-L-(((S)-5-amino-L-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-l-oxopropan-2-yl)-5-guanidinopentanamide in the treatment of neurodegenerative diseases
US11584728B2 (en) 2019-10-04 2023-02-21 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
US11905523B2 (en) 2019-10-17 2024-02-20 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick Disease type-C
CA3166509A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
JP2023511274A (ja) 2020-01-14 2023-03-17 シンセカイン インコーポレイテッド Ｉｌ２オルソログおよび使用法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
KR20230005855A (ko) 2020-04-03 2023-01-10 스텔스 바이오테라퓨틱스 인코포레이티드 프리드리히 운동실조를 포함한 미토콘드리아 질환의 예방 및/또는 치료를 위한 조성물 및 방법
JP2023522933A (ja) 2020-04-23 2023-06-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子操作された食細胞、並びに関連する組成物、ベクター、方法、及びシステム
JP2023535792A (ja) 2020-07-30 2023-08-21 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー コロナウイルス治療のための抗ｃｄ３抗体
KR20230065259A (ko) 2020-08-05 2023-05-11 신테카인, 인크. Il10 수용체 결합 분자 및 사용 방법
WO2022031884A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rg binding molecules and methods of use
IL300736A (en) 2020-08-31 2023-04-01 Kezar Life Sciences Protein secretion inhibitors
CA3197423A1 (en) 2020-11-04 2022-05-12 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
JP2023553343A (ja) 2020-11-25 2023-12-21 アカゲラ・メディスンズ，インコーポレイテッド 核酸を送達するための脂質ナノ粒子および関連する使用方法
EP4291306A1 (de) 2021-02-09 2023-12-20 University of Georgia Research Foundation, Inc. Menschliche monoklonale antikörper gegen pneumokokken-antigene
AU2022365121A1 (en) 2021-10-14 2024-04-18 The Brigham And Women's Hospital, Inc. Methods of suppressing microglial activation
WO2023069255A1 (en) 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023101963A2 (en) 2021-11-30 2023-06-08 Northwestern University Compositions for inhibiting dipeptide repeat protein-ribosomal rna interaction and uses thereof
WO2023133321A1 (en) 2022-01-10 2023-07-13 Stealth Biotherapeutics Inc. Small molecule peptidomimetic for the treatment of tauopathies
WO2023164250A1 (en) 2022-02-28 2023-08-31 Kezar Life Sciences Sec61 inhibitors and use thereof
WO2023198757A1 (en) 2022-04-14 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
GB202214445D0 (en) * 2022-09-30 2022-11-16 Imp College Innovations Ltd Gene therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB354126A (en) * 1929-10-29 1931-08-06 Lucas Haendel Method and device for the production of cigarettes with tobacco coverings
US3826255A (en) * 1972-06-22 1974-07-30 Hudson Oxygen Therapy Sales Co Intermittent positive pressure breathing manifold
YU41046B (en) * 1974-08-22 1986-10-31 Schering Ag Medicine inholating device
US4268460A (en) * 1977-12-12 1981-05-19 Warner-Lambert Company Nebulizer
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4253468A (en) * 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
EP0084898B1 (de) * 1982-01-22 1986-09-03 FISONS plc Liposomen und Natriumcromoglycat enthaltende Präparate und Verfahren zu ihrer Herstellung
US4510929A (en) * 1982-04-30 1985-04-16 Bordoni Maurice E Disposable radioactive aerosol inhalation apparatus
US4649911A (en) * 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3545126A1 (de) * 1985-12-19 1987-06-25 Boehringer Mannheim Gmbh Verfahren zur verbesserung der expression von eukaryontenprotein
US5032407A (en) * 1987-01-16 1991-07-16 Ohio University Edison Animal Biotechnology Center Gene transfer using transformed, neodetermined, embryonic cells
EP0281246A3 (de) * 1987-02-04 1989-07-12 Invitron Corporation Verfahren zur Erhöhung der Amplifikation und Expression fremder Gene
US5075229A (en) * 1987-06-16 1991-12-24 Ohio University Edison Animal Biotechnology Center Dietary and hormonal regulation of expression of exogenous genes in transgenic animals under control of the promoter of the gene for phosphoenolpyruvate carboxykinase
EP0377676B1 (de) * 1987-09-17 1995-05-24 Massachusetts Institute Of Technology Menschliche, erythroid-spezifische transkriptionsenhancer
CA1339654C (en) * 1988-06-03 1998-02-03 Ursula A. Germann Gene therapy using gene fusion for genetic or acquired disorders
US4923949A (en) * 1988-08-03 1990-05-08 Kanegafuchi Chemical Industry Co., Ltd. Ethynylene-disilanylene copolymers and method of preparing same
EP0456640A1 (de) * 1988-12-13 1991-11-21 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Genetisch erzeugte endothelzellen und deren verwendung
JPH04503957A (ja) * 1989-03-07 1992-07-16 ジェネンテク，インコーポレイテッド 脂質とオリゴヌクレオチドの共有結合コンジュゲート
ES2200016T3 (es) * 1989-03-21 2004-03-01 Vical Incorporated Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
GB8909218D0 (en) * 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
US5240842A (en) * 1989-07-11 1993-08-31 Biotechnology Research And Development Corporation Aerosol beam microinjector
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
DK0489058T3 (da) * 1989-08-22 2004-03-22 Univ Michigan Cystisk fibrose gen
GB9020632D0 (en) * 1990-09-21 1990-10-31 Hsc Res Dev Corp Stable propagation of modified full length cystic fibrosis transmembrane conductance regulator protein cdna in heterologous systems
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
DK0452457T3 (da) * 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
CA2037478A1 (en) * 1990-03-05 1991-09-06 Richard Gregory Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
ES2078521T3 (es) * 1990-05-18 1995-12-16 Boehringer Ingelheim Int Nuevos conjugados de proteina-polication.
IT1246763B (it) 1990-07-11 1994-11-26 Frattini Costr Mecc Procedimento di trafilatura a caldo, specie su corpi estrusi od imbutiti ottenuti in alluminio ed apparecchiatura per l'attuazione delprocedimento
JPH04252128A (ja) * 1990-08-03 1992-09-08 Systemix Inc 免疫化された宿主における変性された異種移植器官系
WO1992019749A1 (en) * 1991-05-03 1992-11-12 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Targeted delivery of genes encoding cell surface receptors
WO1993003709A1 (en) * 1991-08-16 1993-03-04 Vical, Inc. Composition and method for treating cystic fibrosis
CA2116107A1 (en) * 1991-09-05 1993-03-18 George Y. Wu Targeted delivery of poly-or oligonucleotides to cells
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CA2126101A1 (en) * 1991-12-17 1993-06-24 Robert J. Debs Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
IL105914A0 (en) * 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy

Also Published As

Publication number Publication date
EP0619742A1 (de) 1994-10-19
US6468798B1 (en) 2002-10-22
JPH07505134A (ja) 1995-06-08
EP0619742A4 (en) 1997-06-04
DE69232815D1 (de) 2002-11-21
CA2126103C (en) 2002-12-03
US5641662A (en) 1997-06-24
CA2126103A1 (en) 1993-07-08
US5858784A (en) 1999-01-12
WO1993012756A2 (en) 1993-07-08
JP2002003383A (ja) 2002-01-09
EP0619742B1 (de) 2002-10-16
WO1993012756A3 (en) 1994-09-01
AU679170B2 (en) 1997-06-26
ES2185624T3 (es) 2003-05-01
AU3329193A (en) 1993-07-28

Similar Documents

Publication Publication Date Title
DE69232815T2 (de) Lungentransfektion durch verabreichung von transgenen im aerosol
DE69735763D1 (de) Intravaskuläre verabreichung von medikamenten durch elektroporation
DE69226921D1 (de) System zur Beendigung von durch einen Herzschrittmacher induzierten Tachykardien bei frequenzadaptierender Reizung
DE69133314D1 (de) Aerosolzubereitungen zur dosierten Abgabe
DE69207228D1 (de) Isolierverfahren von Proteinen durch Ultrafiltration
AU613227B2 (en) Swimming pool cleaner
DK619688D0 (da) Resuscitator til engangsbrug
DK479189D0 (da) Inhalator
DE69217483T2 (de) Abgabegerät von alkoholfreien getränken
IT1096151B (it) Respiratore artificiale automatico,in particolare per sale di rianimazione e per anestesia
DK168190A (da) Interferonpraeparat til nasal anvendelse
ITMI922721A0 (it) Composizioni farmaceutiche contenenti acido ursodesossicolico
NO161835C (no) Synergisk herbicid-blanding inneholdende n-fosfonometylglycin og aryloksyfenoksypentansyreestere.
NO891653L (no) Aminosyreestere og deres fremstilling.
DK220389D0 (da) Synergistiske kombinationspraeparater og deres anvendelse som terapeutika
IT207178Z2 (it) Elemento modulare componibile particolarmente per l'allestimento di controsoffittature, piani divisori e pareti non strutturali in genere.
DK569587D0 (da) Lugtstofkomposition og dispenser herfor
IT8048667A0 (it) Struttura modulare in legno per giochi all'aperto
KR890021386U (ko) 초음파 가습기 노즐
IT1195378B (it) Perfezionamenti relativi a casseforme componibili,construttura modulare,per l'impiego dei tradizionali pannelli in legno da armature
AU531936B3 (en) Improvements in swimming pool construction
ES1016313Y (es) Juguete volador.
DK452084D0 (da) 7beta-acylamido-3-cephem-4-carboxylsyreestere samt deres fremstilling og anvendelse
IT8321884V0 (it) Interruttore bipolare o unipolare di tipo modulare e componibile.
IT8102505A0 (it) Cassaforma componibile, con struttura modulare per l'impiego dei tradizionali pannelli in legno per armature.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee